Innovative Nano-Biosensor Developed for Rapid Detection of Viruses
|
By LabMedica International staff writers Posted on 23 Mar 2016 |

Image: A novel nano-biosensor has been developed for lower-cost, rapid virus detection based on upconversion luminescence resonance energy transfer (LRET) technology and DNA oligo hybridization. Testing takes only 2–3 hours, about 10x faster traditional clinical methods (Photo courtesy of the Hong Kong Polytechnic University).
Scientists have invented a compact, easy-to-use biosensor for rapid, sensitive detection of flu and other viruses by utilizing the optical method of upconversion luminescence resonance energy transfer (LRET).
The new method, invented by researchers at the Hong Kong Polytechnic University (PolyU; Hong Kong), involves simple operational procedures that significantly reduce testing time from around 1–3 days to 2–3 hours, making it over 10 times quicker than traditional clinical methods. Furthermore, it is a low-cost test—about 80% lower than traditional tests, and the technology can be widely used to detect different types of viruses
RT-PCR is expensive and time-consuming while the sensitivity for ELISA is relatively low. Such limitations make these methods difficult for use in front-line and on-site virus detection. This challenge paved the way for the researchers to develop a new biosensor based on the luminescent technique.
The luminescent technique operates analogous to two matching pieces of magnet with attraction force. It involves the development of upconversion nanoparticles (UCNPs) conjugated with an oligo probe whose DNA base pairs are complementary with that of the gold nanoparticles (AuNPs) flu virus oligo. Given the complementarity, the two oligos undergo DNA-DNA hybridization. Upon being illuminated by a portable near-infrared laser pen, the UCNPs emit eye-visible green light while the AuNPs would absorb the green light. One can easily quantify the concentration of the targeted flu virus by measuring the decrease in green light intensity.
Initially, the researchers used upconversion LRET for ultrasensitive virus detection in liquid-phase system. The team then further improved the sensitivity by using a solid-phased nanoporous membrane system (NAAO). As NAAO membrane consists of many hollow channels, it allows more space for oligo hybridization to take place, increasing sensitivity by over 10 folds compared to the liquid-phase system, based on detection using inactivated virus samples.
The new biosensor does not require expensive instruments and sophisticated operational skills, and has sensitivity comparable to traditional clinical methods. In comparison to conventional downconversion luminescent technique, it causes low damage to genetic materials and does not induce background fluorescence. In addition, a complementary probe can be designed to target detection of any virus with known genetic sequence. In other words, the new method can be widely used for the detection of different types of viruses simply by modifying the UCNPs capture probe.
The team will continue to enhance the biosensor for virus detection, including increasing sensitivity and specificity, and developing a matrix for multiplex detection of multiple flu viruses on a single testing platform.
The related results have been recently published in the two nanomaterial research journals ACS Nano and Small.
Related Links:
The Hong Kong Polytechnic University
The new method, invented by researchers at the Hong Kong Polytechnic University (PolyU; Hong Kong), involves simple operational procedures that significantly reduce testing time from around 1–3 days to 2–3 hours, making it over 10 times quicker than traditional clinical methods. Furthermore, it is a low-cost test—about 80% lower than traditional tests, and the technology can be widely used to detect different types of viruses
RT-PCR is expensive and time-consuming while the sensitivity for ELISA is relatively low. Such limitations make these methods difficult for use in front-line and on-site virus detection. This challenge paved the way for the researchers to develop a new biosensor based on the luminescent technique.
The luminescent technique operates analogous to two matching pieces of magnet with attraction force. It involves the development of upconversion nanoparticles (UCNPs) conjugated with an oligo probe whose DNA base pairs are complementary with that of the gold nanoparticles (AuNPs) flu virus oligo. Given the complementarity, the two oligos undergo DNA-DNA hybridization. Upon being illuminated by a portable near-infrared laser pen, the UCNPs emit eye-visible green light while the AuNPs would absorb the green light. One can easily quantify the concentration of the targeted flu virus by measuring the decrease in green light intensity.
Initially, the researchers used upconversion LRET for ultrasensitive virus detection in liquid-phase system. The team then further improved the sensitivity by using a solid-phased nanoporous membrane system (NAAO). As NAAO membrane consists of many hollow channels, it allows more space for oligo hybridization to take place, increasing sensitivity by over 10 folds compared to the liquid-phase system, based on detection using inactivated virus samples.
The new biosensor does not require expensive instruments and sophisticated operational skills, and has sensitivity comparable to traditional clinical methods. In comparison to conventional downconversion luminescent technique, it causes low damage to genetic materials and does not induce background fluorescence. In addition, a complementary probe can be designed to target detection of any virus with known genetic sequence. In other words, the new method can be widely used for the detection of different types of viruses simply by modifying the UCNPs capture probe.
The team will continue to enhance the biosensor for virus detection, including increasing sensitivity and specificity, and developing a matrix for multiplex detection of multiple flu viruses on a single testing platform.
The related results have been recently published in the two nanomaterial research journals ACS Nano and Small.
Related Links:
The Hong Kong Polytechnic University
Latest Technology News
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Distinguishes Deadly Cardiac Events
Two life-threatening cardiovascular emergencies—myocardial infarction and aortic dissection—often present with the same symptom: sudden, severe chest pain. Yet the treatments for these conditions are fundamentally... Read more
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read moreMolecular Diagnostics
view channel
Alzheimer's Blood Marker Could Improve Detection of Heart and Kidney Diseases
A blood protein widely used as an early indicator of Alzheimer’s disease may not be as specific as once thought. Researchers have now found that phosphorylated tau (pTau), a key biomarker linked to ne... Read more
Single Blood Test Predicts Heart Diseases 15 Years Before Onset
Cardiovascular diseases remain the leading cause of death worldwide, claiming nearly 19.8 million lives in 2022 alone. Early identification of individuals at risk is critical for prevention, yet conventional... Read more
New Blood Test Aims to Transform Liver Cancer Surveillance
Liver cancer is one of the fastest‑growing causes of cancer‑related death in the U.S., and surveillance programs face gaps in performance and patient adherence that contribute to late diagnoses.... Read more
Blood Immune 'Fingerprint' Predicts Side Effects of New Alzheimer's Drug
New antibody therapies for Alzheimer’s disease have shown promise in slowing disease progression, but their broader use has been limited by a common side effect known as amyloid-related imaging abnormalities (ARIA).... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read morePathology
view channel
New Chromogenic Culture Media Enable Rapid Detection of Candida Infections
Invasive Candida infections are challenging for healthcare systems, with some strains spreading rapidly in hospitals and showing resistance to multiple antifungal drugs. Candida auris is associated with... Read more
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read moreTechnology
view channel
New Electronic Pipette Enhances Workflows with Touchscreen Control
Manual pipetting remains a routine yet error-prone step that can affect reproducibility and throughput in clinical and research laboratories. Training demands and ergonomic strain also add variability... Read more
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
New Partnership Brings Alzheimer’s Blood Biomarker Test to Community Screening Network
Lucent Diagnostics, a brand of Quanterix Corporation, has partnered with Life Line Screening (LLS) to offer Lucent’s non‑invasive, blood‑based biomarker test across the United States. Programs are... Read more
MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more








